Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Cannabis Bioscience International Holdings EV-to-FCF?
Cannabis Bioscience International HoldingsCBIH +33.33% EV-to-FCF is -10.19 as of Aug. 03, 2026. The stock has 4 warning signs investors should review. Among 571 Drug Manufacturers companies, Cannabis Bioscience International Holdings ranks worse than 175131.17% on this metric.
CBIH'
s EV-to-FCF Range Over the Past 10 Years
Min: -10.19 Med: 0 Max: 0
Current: -10.19
CBIH's EV-to-FCF is ranked worse than 100% of 571
companies
in the Drug Manufacturers industry
Industry Median: 20.7
vs CBIH: -10.19
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cannabis Bioscience International Holdings (OTCPK:CBIH) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cannabis Bioscience International Holdings's PE Ratio (TTM) for today is calculated as:
Cannabis Bioscience International Holdings's share price for today is $0.0002.
Cannabis Bioscience International Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cannabis Bioscience International Holdings EV-to-FCF Related Terms
Cannabis Bioscience International Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabis Bioscience International Holdings EV-to-FCF Chart
Cannabis Bioscience International Holdings Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannabis Bioscience International Holdings EV-to-FCF vs Drug Manufacturers Industry
Cannabis Bioscience International Holdings's current Enterprise Value is $2.73 Mil.
Cannabis Bioscience International Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabis Bioscience International Holdings (CBIH) has a EV-to-FCF of -10.19 as of Aug. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cannabis Bioscience International Holdings and its competitors. According to the industry distribution chart, Cannabis Bioscience International Holdings ranks #999999 out of 571 companies in the Drug Manufacturers industry.
Is Cannabis Bioscience International Holdings' EV-to-FCF too high?
Cannabis Bioscience International Holdings' current EV-to-FCF is -10.19. Based on the distribution chart, Cannabis Bioscience International Holdings ranks #999999 out of 571 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Cannabis Bioscience International Holdings' EV-to-FCF compare to SXTC and UPC?
According to the Drug Manufacturers industry distribution chart, Cannabis Bioscience International Holdings ranks #999999 out of 571 companies for EV-to-FCF. This places Cannabis Bioscience International Holdings in the lower half of its industry. The industry median EV-to-FCF is 20.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.70, based on 571 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cannabis Bioscience International Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Bioscience International Holdings's current EV-to-FCF is -10.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Bioscience International Holdings stock overvalued right now?
Cannabis Bioscience International Holdings (CBIH) has a current EV-to-FCF of -10.19. The current EV-to-FCF is -10.19. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cannabis Bioscience International Holdings (CBIH), the current EV-to-FCF is -10.19 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cannabis Bioscience International Holdings Inc operates in three main areas. Firstly, the company engages in cannabis-related research and education under the trade name Pharmacology University. Secondly, it serves as both a Sponsor and a Contract Research Organization (CRO) in clinical trials, some of which involve cannabis and CBD products, under the trade name Alpha Research Institute. Lastly, the company plans to manufacture, market, and sell CBD products branded as "VitaCookies." The majority of the company's revenue comes from clinical trial contracts, while a smaller portion is generated from cannabis-related educational classes and seminars.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIH has been successfully added to your 
